Last reviewed · How we verify
Aciclovir
Aciclovir, marketed by Assistance Publique Hopitaux De Marseille, is a well-established treatment for encephalitis due to Herpesvirus. The drug's key strength lies in its mechanism of action, which effectively targets the viral infection. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Aciclovir |
|---|---|
| Sponsor | Assistance Publique Hopitaux De Marseille |
| Target | Purine nucleoside phosphorylase, DNA polymerase catalytic subunit, Purine nucleoside phosphorylase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
- Encephalitis due to Herpesvirus
- Genital herpes simplex
- Herpes labialis
- Herpes simplex
- Herpes simplex infection of skin
- Herpes zoster
- Recurrent Mucocutaneous Herpes Simplex
- Recurrent genital herpes simplex
- Recurrent herpes simplex labialis
- Suppression of Recurrent Herpes Simplex Infection
- Varicella
Common side effects
Key clinical trials
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection (PHASE2)
- Impact of Obesity on Clinical Outcomes in Patients Receiving Acyclovir for HSV Encephalitis"
- A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec (PHASE2)
- Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors (PHASE1)
- Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors (PHASE1)
- Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia (PHASE2)
- Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aciclovir CI brief — competitive landscape report
- Aciclovir updates RSS · CI watch RSS
- Assistance Publique Hopitaux De Marseille portfolio CI